• Publications
  • Influence
Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli.
CD2(+) T lymphocytes obtained from either the donor of bone marrow stromal cells (BMSCs) or a third party were cultured in mixed lymphocyte reactions (MLRs) with either allogeneic dendritic cellsExpand
  • 2,858
  • 110
Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data.
BACKGROUND We aimed to assess the clinical validity of circulating tumour cell (CTC) quantification for prognostication of patients with metastatic breast cancer by undertaking a pooled analysis ofExpand
  • 536
  • 13
  • PDF
CCR3 is a target for age-related macular degeneration diagnosis and therapy
Age-related macular degeneration (AMD), a leading cause of blindness worldwide, is as prevalent as cancer in industrialized nations. Most blindness in AMD results from invasion of the retina byExpand
  • 207
  • 13
  • PDF
Transdifferentiation of retinal pigment epithelial cells from epithelial to mesenchymal phenotype.
PURPOSE To describe and evaluate retinal pigment epithelial (RPE) cell transdifferentiation in vitro and to determine its importance to the development of proliferative vitreoretinal disorders. Expand
  • 224
  • 8
  • PDF
Cetuximab and Radiotherapy Versus Cisplatin and Radiotherapy for Locally Advanced Head and Neck Cancer: A Randomized Phase II Trial.
PURPOSE No randomized trials have been conducted to directly compare radiotherapy (RT) with concomitant cisplatin (CDDP) versus concomitant cetuximab (CTX) as first-line treatment of locally advancedExpand
  • 154
  • 7
The role of vascular endothelial growth factor and other endogenous interplayers in age-related macular degeneration
Age-related macular degeneration (AMD) is a multifaceted disease characterized by early subclinical changes at the choroidea-retinal pigment epithelium interface. Both the causal and formalExpand
  • 140
  • 6
Vitreous levels of bevacizumab and vascular endothelial growth factor-A in patients with choroidal neovascularization.
PURPOSE To investigate the vitreous levels of bevacizumab and vascular endothelial growth factor-A (VEGF-A) after intravitreal injection of the drug in patients with choroidal neovascularizationExpand
  • 137
  • 6
Intracameral bevacizumab for iris rubeosis.
PURPOSE To determine whether intracameral bevacizumab decreases vascular leakage from iris rubeosis in patients with neovascular glaucoma. DESIGN Interventional case series. METHODS The studyExpand
  • 185
  • 5
Safety, penetration and efficacy of topically applied bevacizumab: evaluation of eyedrops in corneal neovascularization after chemical burn
Purpose:  That vascular endothelial growth factor (VEGF) plays a major role in inflammatory angiogenesis has been well established. This pilot study was designed to evaluate experimental treatmentExpand
  • 148
  • 5
The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper.
BACKGROUND The heterogeneity of metastatic breast cancer (MBC) necessitates novel biomarkers allowing stratification of patients for treatment selection and drug development. We propose to use theExpand
  • 77
  • 5
...
1
2
3
4
5
...